Kostas Biliouris
Stock Analyst at BMO Capital
(1.12)
# 3,826
Out of 5,084 analysts
62
Total ratings
34.69%
Success rate
-13.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $50 | $22.42 | +123.02% | 9 | Sep 22, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $450 → $470 | $469.83 | +0.04% | 6 | Sep 8, 2025 | |
| IONS Ionis Pharmaceuticals | Upgrades: Outperform | $40 → $70 | $83.14 | -15.80% | 3 | Sep 3, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Market Perform | $15 → $4 | $1.81 | +120.99% | 1 | Jul 8, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $30 → $8 | $3.43 | +133.24% | 2 | May 28, 2025 | |
| RNA Avidity Biosciences | Initiates: Outperform | $72 | $71.65 | +0.49% | 1 | Mar 12, 2025 | |
| DYN Dyne Therapeutics | Initiates: Outperform | $50 | $20.47 | +144.26% | 1 | Mar 12, 2025 | |
| SLN Silence Therapeutics | Maintains: Outperform | $67 → $25 | $6.89 | +262.84% | 2 | Mar 4, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $70 → $50 | $9.63 | +419.21% | 6 | Jan 10, 2025 | |
| DTIL Precision BioSciences | Upgrades: Outperform | $34 | $5.03 | +575.94% | 3 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $35 | $29.33 | +19.33% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $17 | $1.80 | +844.44% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $40 | $11.12 | +259.87% | 4 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 | $28.77 | +212.83% | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 | $6.66 | +1,701.80% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 | $28.39 | +100.77% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $37 | $74.51 | -50.34% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $100 | $53.83 | +85.77% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $4.00 | +375.00% | 1 | Oct 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $98 | $58.30 | +68.10% | 1 | Jun 17, 2022 |
Sarepta Therapeutics
Sep 22, 2025
Upgrades: Outperform
Price Target: $50
Current: $22.42
Upside: +123.02%
Alnylam Pharmaceuticals
Sep 8, 2025
Maintains: Outperform
Price Target: $450 → $470
Current: $469.83
Upside: +0.04%
Ionis Pharmaceuticals
Sep 3, 2025
Upgrades: Outperform
Price Target: $40 → $70
Current: $83.14
Upside: -15.80%
Jasper Therapeutics
Jul 8, 2025
Downgrades: Market Perform
Price Target: $15 → $4
Current: $1.81
Upside: +120.99%
Rocket Pharmaceuticals
May 28, 2025
Maintains: Outperform
Price Target: $30 → $8
Current: $3.43
Upside: +133.24%
Avidity Biosciences
Mar 12, 2025
Initiates: Outperform
Price Target: $72
Current: $71.65
Upside: +0.49%
Dyne Therapeutics
Mar 12, 2025
Initiates: Outperform
Price Target: $50
Current: $20.47
Upside: +144.26%
Silence Therapeutics
Mar 4, 2025
Maintains: Outperform
Price Target: $67 → $25
Current: $6.89
Upside: +262.84%
Intellia Therapeutics
Jan 10, 2025
Maintains: Outperform
Price Target: $70 → $50
Current: $9.63
Upside: +419.21%
Precision BioSciences
Jan 10, 2025
Upgrades: Outperform
Price Target: $34
Current: $5.03
Upside: +575.94%
Sep 16, 2024
Maintains: Outperform
Price Target: $20 → $35
Current: $29.33
Upside: +19.33%
Aug 15, 2024
Maintains: Outperform
Price Target: $22 → $17
Current: $1.80
Upside: +844.44%
Jul 18, 2024
Maintains: Outperform
Price Target: $63 → $40
Current: $11.12
Upside: +259.87%
Jul 3, 2024
Maintains: Outperform
Price Target: $90
Current: $28.77
Upside: +212.83%
May 15, 2024
Maintains: Outperform
Price Target: $120
Current: $6.66
Upside: +1,701.80%
Mar 27, 2024
Maintains: Outperform
Price Target: $57
Current: $28.39
Upside: +100.77%
Jan 31, 2024
Initiates: Market Perform
Price Target: $37
Current: $74.51
Upside: -50.34%
Nov 3, 2023
Maintains: Outperform
Price Target: $102 → $100
Current: $53.83
Upside: +85.77%
Oct 9, 2023
Initiates: Outperform
Price Target: $19
Current: $4.00
Upside: +375.00%
Jun 17, 2022
Initiates: Outperform
Price Target: $98
Current: $58.30
Upside: +68.10%